A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A Trial of the Eastern Cooperative Oncology Group

Robert W. Carlson, Anne M. O'Neill, Lori J. Goldstein, Branimir I. Sikic, Neil Abramson, James A. Stewart, Nancy E. Davidson, William C. Wood

Research output: Contribution to journalArticle

Abstract

Background: To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer. Patients and Methods: Limited, multi-institutional, Phase II trial of valspodar at 5 mg/kg/dose orally every 6 hours for 12 doses in combination with paclitaxel 70 mg/m2 administered intravenously as a 3-hour infusion beginning 4 hours after the fifth dose of valspodar, every 3 weeks. Eligible patients had bi-dimensionally measurable metastatic carcinoma of the breast, prior anthracycline therapy or a medical contraindication to anthracycline therapy, no more than one prior chemotherapy for recurrent or metastatic breast cancer, and adequate organ function. Treatment was continued until disease progression or unacceptable toxicity. Results: Thirty-four patients are evaluable for response and 37 for toxicity. Two (6 percent) patients achieved a complete response and 5 (15 percent) a partial response for an objective response rate of 21 percent (95 percent confidence interval of 9 to 38 percent). Median duration of response was 9.7 months (95 percent confidence interval 8.0-17.2 months), median time to progression was 3.3 months (95 percent confidence interval 2.0-4.2 months), and median survival was 12 months (95 percent confidence interval 8.1-17.3 months). The toxicity experienced was acceptable. Conclusions: Combination valspodar plus paclitaxel is an active regimen and has acceptable toxicity. The combination is not clearly more active than single agent paclitaxel.

Original languageEnglish (US)
Pages (from-to)677-681
Number of pages5
JournalCancer Investigation
Volume24
Issue number7
DOIs
StatePublished - Sep 1 2006

Fingerprint

Multiple Drug Resistance
Paclitaxel
Breast Neoplasms
Anthracyclines
Confidence Intervals
Therapeutics
Disease Progression
valspodar
Drug Therapy
Survival

Keywords

  • Breast neoplasms
  • Multidrug resistance
  • Paclitaxel
  • Valdospar

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195) : A Trial of the Eastern Cooperative Oncology Group. / Carlson, Robert W.; O'Neill, Anne M.; Goldstein, Lori J.; Sikic, Branimir I.; Abramson, Neil; Stewart, James A.; Davidson, Nancy E.; Wood, William C.

In: Cancer Investigation, Vol. 24, No. 7, 01.09.2006, p. 677-681.

Research output: Contribution to journalArticle

Carlson, Robert W. ; O'Neill, Anne M. ; Goldstein, Lori J. ; Sikic, Branimir I. ; Abramson, Neil ; Stewart, James A. ; Davidson, Nancy E. ; Wood, William C. / A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195) : A Trial of the Eastern Cooperative Oncology Group. In: Cancer Investigation. 2006 ; Vol. 24, No. 7. pp. 677-681.
@article{27a1c01f2e7745479d34f5a1958cf7ba,
title = "A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A Trial of the Eastern Cooperative Oncology Group",
abstract = "Background: To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer. Patients and Methods: Limited, multi-institutional, Phase II trial of valspodar at 5 mg/kg/dose orally every 6 hours for 12 doses in combination with paclitaxel 70 mg/m2 administered intravenously as a 3-hour infusion beginning 4 hours after the fifth dose of valspodar, every 3 weeks. Eligible patients had bi-dimensionally measurable metastatic carcinoma of the breast, prior anthracycline therapy or a medical contraindication to anthracycline therapy, no more than one prior chemotherapy for recurrent or metastatic breast cancer, and adequate organ function. Treatment was continued until disease progression or unacceptable toxicity. Results: Thirty-four patients are evaluable for response and 37 for toxicity. Two (6 percent) patients achieved a complete response and 5 (15 percent) a partial response for an objective response rate of 21 percent (95 percent confidence interval of 9 to 38 percent). Median duration of response was 9.7 months (95 percent confidence interval 8.0-17.2 months), median time to progression was 3.3 months (95 percent confidence interval 2.0-4.2 months), and median survival was 12 months (95 percent confidence interval 8.1-17.3 months). The toxicity experienced was acceptable. Conclusions: Combination valspodar plus paclitaxel is an active regimen and has acceptable toxicity. The combination is not clearly more active than single agent paclitaxel.",
keywords = "Breast neoplasms, Multidrug resistance, Paclitaxel, Valdospar",
author = "Carlson, {Robert W.} and O'Neill, {Anne M.} and Goldstein, {Lori J.} and Sikic, {Branimir I.} and Neil Abramson and Stewart, {James A.} and Davidson, {Nancy E.} and Wood, {William C.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1080/07357900600981349",
language = "English (US)",
volume = "24",
pages = "677--681",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195)

T2 - A Trial of the Eastern Cooperative Oncology Group

AU - Carlson, Robert W.

AU - O'Neill, Anne M.

AU - Goldstein, Lori J.

AU - Sikic, Branimir I.

AU - Abramson, Neil

AU - Stewart, James A.

AU - Davidson, Nancy E.

AU - Wood, William C.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Background: To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer. Patients and Methods: Limited, multi-institutional, Phase II trial of valspodar at 5 mg/kg/dose orally every 6 hours for 12 doses in combination with paclitaxel 70 mg/m2 administered intravenously as a 3-hour infusion beginning 4 hours after the fifth dose of valspodar, every 3 weeks. Eligible patients had bi-dimensionally measurable metastatic carcinoma of the breast, prior anthracycline therapy or a medical contraindication to anthracycline therapy, no more than one prior chemotherapy for recurrent or metastatic breast cancer, and adequate organ function. Treatment was continued until disease progression or unacceptable toxicity. Results: Thirty-four patients are evaluable for response and 37 for toxicity. Two (6 percent) patients achieved a complete response and 5 (15 percent) a partial response for an objective response rate of 21 percent (95 percent confidence interval of 9 to 38 percent). Median duration of response was 9.7 months (95 percent confidence interval 8.0-17.2 months), median time to progression was 3.3 months (95 percent confidence interval 2.0-4.2 months), and median survival was 12 months (95 percent confidence interval 8.1-17.3 months). The toxicity experienced was acceptable. Conclusions: Combination valspodar plus paclitaxel is an active regimen and has acceptable toxicity. The combination is not clearly more active than single agent paclitaxel.

AB - Background: To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer. Patients and Methods: Limited, multi-institutional, Phase II trial of valspodar at 5 mg/kg/dose orally every 6 hours for 12 doses in combination with paclitaxel 70 mg/m2 administered intravenously as a 3-hour infusion beginning 4 hours after the fifth dose of valspodar, every 3 weeks. Eligible patients had bi-dimensionally measurable metastatic carcinoma of the breast, prior anthracycline therapy or a medical contraindication to anthracycline therapy, no more than one prior chemotherapy for recurrent or metastatic breast cancer, and adequate organ function. Treatment was continued until disease progression or unacceptable toxicity. Results: Thirty-four patients are evaluable for response and 37 for toxicity. Two (6 percent) patients achieved a complete response and 5 (15 percent) a partial response for an objective response rate of 21 percent (95 percent confidence interval of 9 to 38 percent). Median duration of response was 9.7 months (95 percent confidence interval 8.0-17.2 months), median time to progression was 3.3 months (95 percent confidence interval 2.0-4.2 months), and median survival was 12 months (95 percent confidence interval 8.1-17.3 months). The toxicity experienced was acceptable. Conclusions: Combination valspodar plus paclitaxel is an active regimen and has acceptable toxicity. The combination is not clearly more active than single agent paclitaxel.

KW - Breast neoplasms

KW - Multidrug resistance

KW - Paclitaxel

KW - Valdospar

UR - http://www.scopus.com/inward/record.url?scp=33751501999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751501999&partnerID=8YFLogxK

U2 - 10.1080/07357900600981349

DO - 10.1080/07357900600981349

M3 - Article

C2 - 17118777

AN - SCOPUS:33751501999

VL - 24

SP - 677

EP - 681

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 7

ER -